Head and Neck Cancer Clinical Trial
Official title:
A Randomized Phase III Multicenter Trial of Neoadjuvant Docetaxel (Taxotere) Plus Cisplatin Plus 5-Fluorouracil Versus Neoadjuvant Cisplatin Plus 5-Fluorouracil in Patients With Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
Combining more than one drug and combining chemotherapy with radiation therapy may kill more
tumor cells. It is not yet known which regimen of combination chemotherapy is more effective
for advanced head and neck cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of two regimens of
combination chemotherapy plus radiation therapy in treating patients who have advanced head
and neck cancer.
OBJECTIVES: I. Compare the progression free survival of patients with locally advanced,
inoperable squamous cell carcinoma of the head and neck treated with cisplatin plus
fluorouracil with or without docetaxel as a neoadjuvant to radiotherapy. II. Compare the
response rate, response duration, toxicity, local symptoms, and time to disease progression
of these treatment regimens in this patient population. III. Evaluate the quality of life in
these patients.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
primary tumor site (oral cavity vs oropharynx vs hypopharynx vs larynx) and institution.
Patients are randomized to one of two treatment arms. Arm I: Patients receive docetaxel IV
over 1 hour, immediately followed by cisplatin IV over 1 hour on day 1 and fluorouracil
(5-FU) IV as a continuous infusion on days 1-5. Arm II: Patients receive cisplatin IV over 1
hour on day 1 followed by 5-FU IV as a continuous infusion on days 1-5. Treatment continues
every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
Patients receive radiotherapy following chemotherapy within 3-6 weeks of last course.
Radiotherapy is administered 5 days a week for up to 7 weeks. Quality of life is assessed
before treatment, at courses 2 and 4, and at 6 and 9 months. Patients are followed every 3
months for the first 2 years and then every 6 months until death.
PROJECTED ACCRUAL: A total of 348 patients will be accrued for this study within 24 months.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05808920 -
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03997643 -
Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04700475 -
Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients.
|
N/A | |
Withdrawn |
NCT04058145 -
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02572869 -
Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
|
||
Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05073809 -
Photoacoustic Imaging of Head and Neck Tumours
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03651570 -
Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study
|
N/A | |
Recruiting |
NCT04930432 -
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06016699 -
Immunological Function After Radiation With Either Proton or Photon Therapy
|
||
Terminated |
NCT03843554 -
Commensal Oral Microbiota in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05915572 -
Mulligan Technique on Shoulder Dysfunction
|
N/A | |
Completed |
NCT05897983 -
Tens and Rocabado Exercises on TMJ Dysfunction
|
N/A | |
Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
Withdrawn |
NCT05263648 -
Virtual Reality Software to Reduce Stress in Cancer Patients
|
N/A | |
Withdrawn |
NCT03238638 -
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
|
Phase 2 |